A functional variant in the serotonin transporter promoter, 5-HTTLPR, has recently been shown to be associated with SAD and seasonality. The purpose of this study was to determine whether −1438G/A, a polymorphism in the 5-HT 2A promoter, is associated with SAD and seasonality, and whether it has additive effects with 5-HTTLPR on seasonality. Sixty-seven individuals with SAD and 69 normal volunteers, all screened with the SCID and diagnosed according to DSM-III-R criteria, were genotyped for the −1438G/A 5-HT 2A promoter polymorphism. All had been previously genotyped for 5-HTTLPR and had been assessed for seasonality by the Global Seasonality Scale. There was a significant increase in the frequency of the −1438A variant allele of the 5-HT 2A promoter polymorphism in SAD patients (0.47) compared to matched controls (0.36) (P Ͻ 0.01). The difference in genotype distribution was also significant (P Ͻ 0.05). We found no association between the −1438G/A polymorphism and seasonality scores, and there was no additive effect with 5-HTTLPR on seasonality. In conclusion, we have shown that the −1438G/A 5-HT 2A promoter variant is associated with SAD but not with seasonality. We suggest that the association may instead be with the depressive symptoms of SAD. However, these results should be treated with caution until replicated because of the possibility of false-positive findings in case-control association studies.
Seasonal affective disorder (SAD), a condition in which depression recurs in winter and usually remits in spring, may represent the pathological extreme of seasonal mood changes (or seasonality) which occur in approximately 25% of normal individuals. 1 Apart from depressed mood, SAD is characterized by lack of energy, hypersomnia, overeating, weight gain, and a craving for carbohydrates, and may be induced in vulnerable individuals by diminished winter daylight. 2, 3 Serotonin dysfunction has been implicated in the pathogenesis of SAD. Hypothalamic serotonin, which regulates several physiological functions including appetite and sleep, shows seasonal variation in humans, with lowest levels occurring in winter. 4 Features of SAD such as seasonal hypersomnia, weight gain and impairment of satiety may therefore be related to serotonin dysfunction. CNS serotonergic pathways may be involved in the effective bright light treatment of winter depression in SAD. Animal studies indicate that light regulates serotonin function in the dorsal raphae. 5 Bright light is known to suppress the conversion of serotonin to melatonin in the pineal gland. In addition, dietary depletion of tryptophan, the precursor of serotonin, reverses the beneficial effects of bright light therapy. 6 Pharmacological responses in SAD patients also suggest possible dysfunction in serotonergic transmission. 7 The efficacy of selective serotonin re-uptake inhibitors (SSRIs) in relieving the depressive symptoms of SAD has been demonstrated, particularly sertraline 8 and, to some extent, fluoxetine. 9, 10 Meta-chlorophenylpiperazine (m-CPP), an agonist for several serotonin receptors, mainly 5-HT 2c but also 5-HT 2A and others, increases energy and euphoria in symptomatic SAD patients, but not following light treatment, nor in the summer, nor in controls. 11 Seasonality has been shown to be heritable 12 suggesting that there may be a genetic component to SAD. There is evidence that major depression is heritable. 13 An important starting point for understanding the vulnerability to SAD and seasonality may therefore be to look for variation in the many genes involved in serotonin function. Indeed variants affecting serotonin function have been found, for example, in the genes encoding serotonin metabolising enzymes, 14 serotonin receptors 15, 16 and the serotonin transporter. 17 Recently, 5-HTTLPR, a functional variant in the promoter region of the serotonin transporter, has been shown to be associated with SAD and seasonality. 18 Certain lines of evidence suggest that the 5-HT 2A receptor gene may be one of several genes influencing the pathogenesis of seasonality and SAD. Treatment of SAD symptoms with SSRIs may be partially through downregulation of 5-HT 2A receptors, 19, 20 and it has been suggested that light therapy may work by altering the sensitivity of receptors. 21 Individuals with eating disorders have high levels of seasonality. 22 A polymorphism, −1438G/A, in the 5-HT 2A promoter region was recently found to be associated with anorexia nervosa 23, 24 and obsessive-compulsive disorder (OCD). 24 We hypothesised that of the known 5-HT 2A polymorphisms, the −1438G/A promoter polymorphism would be associated with SAD and seasonality scores, and that the effects on seasonality might be additive with the 5-HTTLPR polymorphism. We therefore genotyped 67 individuals with SAD and 69 matched normal controls for this polymorphism. Table 1 shows the results of the study. It can be seen that we did indeed find a significant increase in the frequency of the −1438A variant allele in SAD patients (0.47) compared to controls (0.36) (P Ͻ 0.01). When SAD patients and controls were compared by genotype, the difference in distribution was also significant ( 2 = 6.85, 2 df, P Ͻ 0.05). The genotype distributions of both populations were in Hardy-Weinberg equilibrium.
We found no association between the −1438G/A polymorphism and seasonality scores. The mean Global Seasonality Score (GSS) of the 62 SAD patients for whom we had data was 16.65, s.d. This study has therefore demonstrated that the variant −1438A allele in the 5-HT 2A promoter polymorphism occurs significantly more often in SAD patients (0.47) compared with controls (0.36) (P Ͻ 0.01). However, there was no association between the Global Seasonality Scores and the 5-HT 2A −1438G/A polymorphism, nor were there additive effects on seasonality with 5-HTTLPR. The fact that the −1438A variant allele is also significantly more common in individuals with anorexia nervosa (0.51) 23 and OCD (0.50) 24 compared with controls (0.41) does suggest that the association might be with a mood disorder. Variation in the 5-HT 2A gene may therefore have effects on other symptoms of SAD, such as depression.
Results of association studies must always be treated with caution until replicated because of the possibility of false positive findings. In this study every effort was made to ensure that the controls, who had low seasonality scores and no psychiatric disorders, were closely matched with SAD patients with respect to age, gender, ethnic background and geographical localization. The frequency of the −1438A variant allele in our controls (0.36) compares closely with the frequencies in Caucasian controls found in other studies (0.41). 23, 24 The observations of an association between the −1438A allele of the 5-HT 2A promoter polymorphism and SAD, anorexia nervosa and OCD, suggest that differences in 5-HT 2A function might correlate with −1438G/A genotype. The 5-HT 2A receptor belongs to the family of G-protein coupled receptors and controls signal transduction by activating phospholipase C. 25 A functional promoter variant of 5-HT 2A might differentially alter transcription, thereby affecting the number of receptors.
The 5-HT 2A receptor gene is expressed both in brain and in platelets, and the functional properties in these two tissues are very similar, 26 enabling studies on 5-HT 2A receptor function to be performed in platelets. 27 It will be important to investigate platelet 5-HT 2A expression in patients with SAD and other forms of depression.
The effectiveness of SSRIs in treating the depressive symptoms of SAD, and the effect of m-CPP, a 5-HT 2A agonist, in increasing energy and euphoria in symptomatic SAD patients, as well as the fact that 5-HT 2A receptor densities have been found to be increased in the platelets of patients with depression, 26 and in suicidal patients 28 suggests that 5-HT 2A is a good candidate gene for the depressive symptoms of SAD.
In conclusion, we have shown that the −1438G/A 5-HT 2A promoter variant is associated with SAD but not with seasonality. We suggest that the association may instead be with the depressive symptoms of SAD. It will be important not only to replicate this study but to screen individuals with non-seasonal major depression for the 5-HT 2A −1438G/A polymorphism. SAD is a complex, multifactorial disease in which many genes, other than the 5-HTT and 5-HT 2A genes, may be involved. Further candidate genes should be sought in order to elucidate the genetic complexity of this disorder.
Methods

Ascertainment
Individuals with SAD and normal volunteers were recruited from the Washington DC/Baltimore metropolitan area (USA) by way of local media. Of those individuals for whom good DNA was available, there were 67 subjects who met the diagnostic criteria of Rosenthal et al 2 for SAD and 69 normal volunteers. All subjects with SAD had been screened with the SCID, had DSM-III-R diagnoses of major depressive disorder and fulfilled the criteria of the Seasonal Pattern Specifier. 29 All were Caucasian, 48 were female, 19 were male and the mean age was 38.2 yrs (s.d. = 8.9).
The controls were carefully matched with subjects for age and gender. Of the 69 normal volunteers all were Caucasian, 44 were female, 25 were male and the mean age was 40.7 yrs (s.d. = 10.7). Normal volunteers, screened with the SCID, were free of psychiatric disorders by DSM-III-R criteria, and had no history of psychiatric disease in first-degree relatives. All had a physical examination to ensure that they were healthy.
All subjects were administered the Seasonal Pattern Assessment Questionnaire (SPAQ), and from this the Global Seasonality Score (GSS) was computed based on six behaviors: sleeping, appetite, mood, energy level, weight, social behavior (range 0-24). The normal volunteers were required to have very low seasonality; ie a GSS of less than 6.
Informed consent was obtained according to a human research protocol approved by the Human Research Committee of the National Institute of Mental Health.
Experimental procedures
A 468-basepair (bp) region in the 5-HT 2A promoter was amplified using the following primers: 5Ј-AAGCTG CAAGGTAGCAACAGC-3Ј and 5Ј-AACCAACTTATT TCCTACCAC-3Ј. 23 The amplification mixture contained 100 g l −1 of DNA, 10 M of each primer, 2.5 mM each of dATP, dCTP, dGTP, dTTP and 5 U per 100 l of AmpliTaq with the appropriate buffer (Perkin Elmer, Applied Biosystems, Foster City, CA, USA) which contained 15 mM KCl. Samples were amplified for 30 cycles, each consisting of 20 s at 95°C, 20 s at 62°C, and 20 s at 72°C. The 468-bp product was digested with Msp1 which cuts at the −1438G site yielding two fragments, 244 and 224 bp in size. Each 10-l digestion mix contained 5 l of PCR product, NEB buffer 2, and 6 units of Msp1. After digestion at 37°C for 4 h, the alleles were resolved on 5% TBE polyacrylamide gels stained with ethidium bromide (1 l per 5 ml). All subjects had been previously genotyped for 5-HTTLPR. 18 
Statistical methods
The chi-square test was used to determine the statistical significance of the differences between the allele and genotype frequencies. A two-way analysis of variance was employed to investigate interactive effects on the GSS in SAD patients between the 5-HT 2A promoter polymorphism and the 5-HTTLPR polymorphism.
